An Experimental Trial to Prepared γ1 34.5 Herpes Simplex Virus 1 Immunogene by cloning Technique
Abstract
Ameer M Hadi, Shakir H. Mohammed Al-Alwany, Zaytoon A. Al-Khafaji
The herpes simplex virus (HSV) family offers particular advantages for use as a viral oncolytic. The engineered vectors that make up oncolytic HSVs (oHSVs) have demonstrated remarkable safety in clinical trials, with some evidence of efficacy. The past decade has seen a focus on increasing the efficacy of oncolytic vectors by adding exogenous transgenes to enhance tumor destruction.
This study aimed to prepared the Recombinant γ1 34.5 - Infected Cell Protein (ICP34.5) Herpes Simplex Virus-1 Immunogenic by cloning technique from the wild type hsv-1, through the following steps; firstly propagation the virus on Vero cell line o estimate the cytopathic effect; after then it was diagnosed by immunofluorescent microscope in cell culture supernatant; followed by evaluation the titration of hsv-1 by plaque assay. Secondly, used specific set of primers for (γ1 34.5 gene) sequence, then cleaved this sequence by restriction enzyme; followed it cloned this sequence by appropriate vector (PSL1180), then was mixed with another vector contain green fluorescent protein to ensure was gained these sequence. Thirdly, transport this sequence to vero cell line by specific transporter for development and produce there gene expression (ICP34.5) immunogenic.
| How to Cite this Article |
| Pubmed Style Ameer M Hadi, Shakir H. Mohammed Al-Alwany, Zaytoon A. Al-Khafaji. An Experimental Trial to Prepared γ1 34.5 Herpes Simplex Virus 1 Immunogene by cloning Technique. SRP. 2020; 11(5): 140-149. doi:10.31838/srp.2020.5.22 Web Style Ameer M Hadi, Shakir H. Mohammed Al-Alwany, Zaytoon A. Al-Khafaji. An Experimental Trial to Prepared γ1 34.5 Herpes Simplex Virus 1 Immunogene by cloning Technique. http://www.sysrevpharm.org/?mno=108397 [Access: March 28, 2021]. doi:10.31838/srp.2020.5.22 AMA (American Medical Association) Style Ameer M Hadi, Shakir H. Mohammed Al-Alwany, Zaytoon A. Al-Khafaji. An Experimental Trial to Prepared γ1 34.5 Herpes Simplex Virus 1 Immunogene by cloning Technique. SRP. 2020; 11(5): 140-149. doi:10.31838/srp.2020.5.22 Vancouver/ICMJE Style Ameer M Hadi, Shakir H. Mohammed Al-Alwany, Zaytoon A. Al-Khafaji. An Experimental Trial to Prepared γ1 34.5 Herpes Simplex Virus 1 Immunogene by cloning Technique. SRP. (2020), [cited March 28, 2021]; 11(5): 140-149. doi:10.31838/srp.2020.5.22 Harvard Style Ameer M Hadi, Shakir H. Mohammed Al-Alwany, Zaytoon A. Al-Khafaji (2020) An Experimental Trial to Prepared γ1 34.5 Herpes Simplex Virus 1 Immunogene by cloning Technique. SRP, 11 (5), 140-149. doi:10.31838/srp.2020.5.22 Turabian Style Ameer M Hadi, Shakir H. Mohammed Al-Alwany, Zaytoon A. Al-Khafaji. 2020. An Experimental Trial to Prepared γ1 34.5 Herpes Simplex Virus 1 Immunogene by cloning Technique. Systematic Reviews in Pharmacy, 11 (5), 140-149. doi:10.31838/srp.2020.5.22 Chicago Style Ameer M Hadi, Shakir H. Mohammed Al-Alwany, Zaytoon A. Al-Khafaji. "An Experimental Trial to Prepared γ1 34.5 Herpes Simplex Virus 1 Immunogene by cloning Technique." Systematic Reviews in Pharmacy 11 (2020), 140-149. doi:10.31838/srp.2020.5.22 MLA (The Modern Language Association) Style Ameer M Hadi, Shakir H. Mohammed Al-Alwany, Zaytoon A. Al-Khafaji. "An Experimental Trial to Prepared γ1 34.5 Herpes Simplex Virus 1 Immunogene by cloning Technique." Systematic Reviews in Pharmacy 11.5 (2020), 140-149. Print. doi:10.31838/srp.2020.5.22 APA (American Psychological Association) Style Ameer M Hadi, Shakir H. Mohammed Al-Alwany, Zaytoon A. Al-Khafaji (2020) An Experimental Trial to Prepared γ1 34.5 Herpes Simplex Virus 1 Immunogene by cloning Technique. Systematic Reviews in Pharmacy, 11 (5), 140-149. doi:10.31838/srp.2020.5.22 |
Abstract
PDF
How to cite this article
Related Records